Dr. Dipesh Uprety, MD

Dr. Uprety practices at McLaren Flint Hospital in Flint, Michigan.

Dr. Uprety's NPI, 1902245269, was assigned on June 20, 2013. Dr. Uprety holds Minnesota license 65187.

Dr. Uprety's primary practice is McLaren Flint Hospital, at 401 S Ballenger Hwy, Flint, MI 48532 in Genesee County. The practice phone is (810) 762-6699.

Dr. Uprety's primary practice is McLaren Flint Hospital in Flint, Michigan. Dr. Uprety is also affiliated with University of Maryland Medical Center. The medical group on file is Barbara Ann Karmanos Cancer Institute. Dmand AI also links Dr. Uprety to 2 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Uprety practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Uprety's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Uprety's licenses on file in 2 states: Minnesota and Wisconsin.

CMS data shows 220 Medicare services from Dr. Uprety across 2 procedure codes in 2024, all of them office visits, for 76 Medicare patients. Medicare paid $19,751 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 76 Medicare patients who saw Dr. Uprety in 2024. The largest group is 65 to 74, with 39 patients. 75% of them have cancer, and 75% have high blood pressure. 45% are also on Medicaid. Their average risk score is 3.80, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Uprety's median patient age at 69, with 51% women.

In 2024, Dr. Uprety wrote 262 Medicare Part D claims for 68 patients. 78% of them were for generic drugs. CMS names the drug for 176 of them, across 10 drugs with 11 or more claims each, at $570,716 in total drug cost. In 2023, CMS named 119 claims across 7 drugs.

Dr. Uprety accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 58 papers to Dr. Uprety, published from 2012 to 2025. 2020 was the busiest year, with 7. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and SEER Program. Dr. Uprety has published most often in J Thorac Oncol. Dr. Uprety's most frequent co-authors are Amir Bista, Hirva Mansurali Mamdani, MD and Yazhini Vallatharasu, MD.

Dmand AI links Dr. Uprety to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Carcinoma, Neuroendocrine and Thyroid Neoplasms.

CMS Open Payments shows 11 general payments to Dr. Uprety from 8 drug and device companies from 2021 to 2025. Consulting fees make up the largest share, 100% of the total. Pfizer Inc. paid the most, $4,730.